Key facts
- Tetraneuron’s last known valuation is $29.0M (Dec 2025).
- It has raised $14.6M; the latest was Later Stage VC ($5.8M) in Dec 2025.
- Notable investors include Johnson & Johnson Innovation - JLABS, GIMIC Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Tetraneuron
- ·The full record, as it builds
Funding rounds
No funding rounds for Tetraneuron are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Tetraneuron
Developer of gene therapies designed to address upstream molecular drivers of neurodegeneration. The company offers AAV9-based therapies that modulate transcription factor activity with neuron-specific targeting and preclinical validation, enabling healthcare providers to treat patients with neurodegenerative disorders with a disease-modifying approach.
- Sector
- Healthcare
- HQ
- Madrid, Spain
- Founded
- 2012
- Employees
- 15
- Website
- tetraneuron.com/
- Ownership
- Privately Held (backing)
Tetraneuron doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tetraneuron shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tetraneuron in its N-PORT filings yet. We sweep new filings monthly.